IL255054A0 - Tetrahydronephthyridinyl propionic acid derivatives and their uses - Google Patents
Tetrahydronephthyridinyl propionic acid derivatives and their usesInfo
- Publication number
- IL255054A0 IL255054A0 IL255054A IL25505417A IL255054A0 IL 255054 A0 IL255054 A0 IL 255054A0 IL 255054 A IL255054 A IL 255054A IL 25505417 A IL25505417 A IL 25505417A IL 255054 A0 IL255054 A0 IL 255054A0
- Authority
- IL
- Israel
- Prior art keywords
- tetrahydronaphthyridinyl
- propionic acid
- acid derivatives
- derivatives
- propionic
- Prior art date
Links
- ZPQLOGVWIFHBAY-UHFFFAOYSA-N 2-(3,4-dihydro-2H-1,8-naphthyridin-1-yl)propanoic acid Chemical class N1(CCCC2=CC=CN=C12)C(C(=O)O)C ZPQLOGVWIFHBAY-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562154894P | 2015-04-30 | 2015-04-30 | |
| PCT/US2016/029962 WO2016176532A1 (en) | 2015-04-30 | 2016-04-29 | Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL255054A0 true IL255054A0 (en) | 2017-12-31 |
Family
ID=56027176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL255054A IL255054A0 (en) | 2015-04-30 | 2017-10-16 | Tetrahydronephthyridinyl propionic acid derivatives and their uses |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9572801B2 (https=) |
| EP (1) | EP3288555A1 (https=) |
| JP (1) | JP2018514568A (https=) |
| KR (1) | KR20170141757A (https=) |
| CN (1) | CN108040467A (https=) |
| AU (1) | AU2016255494A1 (https=) |
| BR (1) | BR112017023432A2 (https=) |
| CA (1) | CA2983312A1 (https=) |
| IL (1) | IL255054A0 (https=) |
| MX (1) | MX2017013880A (https=) |
| RU (1) | RU2017141561A (https=) |
| WO (1) | WO2016176532A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8901144B2 (en) * | 2013-02-07 | 2014-12-02 | Scifluor Life Sciences, Llc | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives |
| HRP20171873T1 (hr) | 2013-02-07 | 2018-02-23 | Scifluor Life Sciences, Inc | Fluorinirani antagonisti integrina |
| KR102647026B1 (ko) | 2015-02-19 | 2024-03-12 | 사이플루어 라이프 사이언시즈, 인크 | 플루오르화 테트라히드로나프티리디닐 노난산 유도체 및 이의 용도 |
| WO2017189828A1 (en) | 2016-04-27 | 2017-11-02 | Scifluor Life Sciences, Inc. | Nonanoic and decanoic acid derivatives and uses thereof |
| MA52117A (fr) | 2017-02-28 | 2022-04-06 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| MA47697A (fr) | 2017-02-28 | 2020-01-08 | Morphic Therapeutic Inc | Inhibiteurs de l'(alpha-v)(bêta-6) intégrine |
| US20210093725A1 (en) * | 2018-04-27 | 2021-04-01 | Arrowhead Pharmaceuticals, Inc. | Integrin targeting ligands and uses thereof |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| FI3844162T3 (fi) | 2018-08-29 | 2025-03-27 | Morphic Therapeutic Inc | Alfa v beeta6 -integriinin estäjiä |
| EP4086254B1 (en) | 2018-08-29 | 2024-12-18 | Morphic Therapeutic, Inc. | Integrin inhibitors |
| WO2021225912A1 (en) * | 2020-05-07 | 2021-11-11 | Pliant Therapeutics, Inc. | Treatment of respiratory diseases with amino acid compounds |
| JP7585564B2 (ja) * | 2020-09-24 | 2024-11-19 | 株式会社ファンケル | セラミド含有ニオソームを含む化粧料 |
| KR20250011204A (ko) * | 2022-05-30 | 2025-01-21 | 시노허브 파마슈티컬 씨오., 엘티디 | 유착 관련 질환을 예방 치료하는 약물의 제조에서 테트라히드로나프티리딘 유도체의 응용 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1318254C (en) | 1988-01-06 | 1993-05-25 | Munehiro Tomikawa | Inhibitory agent of hepatic fibrosis containing pantethine |
| ES2104938T3 (es) | 1991-04-01 | 1997-10-16 | Univ Duke | Metodo de inhibir la fibrosis. |
| JP3818322B2 (ja) | 1994-04-28 | 2006-09-06 | 敏一 中村 | コラーゲン分解促進剤 |
| US5645839A (en) | 1995-06-07 | 1997-07-08 | Trustees Of Boston University | Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis |
| US6664227B1 (en) | 1996-03-01 | 2003-12-16 | Genetics Institute, Llc | Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains |
| AU3215597A (en) | 1996-08-30 | 1998-03-19 | Biomeasure Incorporated | Method of inhibiting fibrosis with a somatostatin agonist |
| CN1284955A (zh) * | 1997-12-17 | 2001-02-21 | 麦克公司 | 整联蛋白受体拮抗剂 |
| US6017926A (en) | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
| US6117445A (en) | 1998-01-28 | 2000-09-12 | Link Technology Inc. | Methods for the prevention and treatment of fibrosis and sclerosis |
| HUP0201284A3 (en) | 2000-02-22 | 2003-02-28 | Daiichi Asubio Pharma Co Ltd | Preventive or therapeutic drugs for fibrosis containing quinazolindione derivative chymase inhibitors as the active ingredient |
| AU2001292598B2 (en) | 2000-09-14 | 2006-06-29 | Merck & Co., Inc. | Alpha V integrin receptor antagonists |
| US6509347B2 (en) | 2001-06-11 | 2003-01-21 | Merck & Co., Inc. | Crystalline forms of an integrin receptor antagonist |
| US8901144B2 (en) * | 2013-02-07 | 2014-12-02 | Scifluor Life Sciences, Llc | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives |
| HRP20171873T1 (hr) | 2013-02-07 | 2018-02-23 | Scifluor Life Sciences, Inc | Fluorinirani antagonisti integrina |
| KR102647026B1 (ko) * | 2015-02-19 | 2024-03-12 | 사이플루어 라이프 사이언시즈, 인크 | 플루오르화 테트라히드로나프티리디닐 노난산 유도체 및 이의 용도 |
| WO2016154369A1 (en) * | 2015-03-26 | 2016-09-29 | Merck Sharp & Dohme Corp. | Composition and methods for treating chronic kidney disease |
-
2016
- 2016-04-29 KR KR1020177034091A patent/KR20170141757A/ko not_active Withdrawn
- 2016-04-29 CN CN201680036759.2A patent/CN108040467A/zh active Pending
- 2016-04-29 US US15/142,023 patent/US9572801B2/en not_active Expired - Fee Related
- 2016-04-29 MX MX2017013880A patent/MX2017013880A/es unknown
- 2016-04-29 AU AU2016255494A patent/AU2016255494A1/en not_active Abandoned
- 2016-04-29 RU RU2017141561A patent/RU2017141561A/ru not_active Application Discontinuation
- 2016-04-29 BR BR112017023432A patent/BR112017023432A2/pt not_active Application Discontinuation
- 2016-04-29 JP JP2017556988A patent/JP2018514568A/ja not_active Withdrawn
- 2016-04-29 EP EP16724172.8A patent/EP3288555A1/en not_active Withdrawn
- 2016-04-29 WO PCT/US2016/029962 patent/WO2016176532A1/en not_active Ceased
- 2016-04-29 CA CA2983312A patent/CA2983312A1/en not_active Abandoned
-
2017
- 2017-10-16 IL IL255054A patent/IL255054A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016176532A1 (en) | 2016-11-03 |
| MX2017013880A (es) | 2018-08-01 |
| BR112017023432A2 (pt) | 2018-07-24 |
| US9572801B2 (en) | 2017-02-21 |
| RU2017141561A3 (https=) | 2019-09-25 |
| EP3288555A1 (en) | 2018-03-07 |
| US20160317527A1 (en) | 2016-11-03 |
| AU2016255494A1 (en) | 2017-11-02 |
| CN108040467A (zh) | 2018-05-15 |
| CA2983312A1 (en) | 2016-11-03 |
| RU2017141561A (ru) | 2019-05-31 |
| JP2018514568A (ja) | 2018-06-07 |
| KR20170141757A (ko) | 2017-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL278916A (en) | Benzoimidazole derivatives as PAD4 inhibitors | |
| IL255054A0 (en) | Tetrahydronephthyridinyl propionic acid derivatives and their uses | |
| ZA201808327B (en) | Boronic acid derivatives and therapeutic uses thereof | |
| IL267239A (en) | New derivatives of phenylpropionic acid and their uses | |
| IL253873A0 (en) | Fluorine tetrahydronaphthyridinyl nonanoic acid derivatives and their uses | |
| ZA201608682B (en) | Boronic acid derivatives and therapeutic uses thereof | |
| IL252135B (en) | Triazolopyrimidine compounds and their uses | |
| EP3145936A4 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| SG11201701292XA (en) | Topical formulation | |
| EP3099171A4 (en) | Dihydropteridinone derivatives and uses thereof | |
| ZA201703007B (en) | Boronic acid derivatives | |
| GB201407934D0 (en) | Formulation | |
| SG11201702625PA (en) | Boronic acid derivatives | |
| EP3154972A4 (en) | Azamophinan derivatives and use thereof | |
| SG11201702620SA (en) | Boronic acid derivatives | |
| SG11201702623TA (en) | Boronic acid derivatives | |
| EP3177147A4 (en) | Dihydropteridinone derivatives and uses thereof | |
| IL247148A0 (en) | Pyrazolone compounds and uses thereof | |
| DK3200779T3 (en) | Novel anthranilic acid derivatives | |
| PT3672977T (pt) | Derivados do ácido borónico | |
| GB201407384D0 (en) | Formulation | |
| IL259073A (en) | History of abscisic acid - converted at the 3' position | |
| GB201806645D0 (en) | Towing assistance | |
| EP3155113A4 (en) | Organic acids from homocitrate and homocitrate derivatives | |
| HK1260336A1 (en) | Valbenazine salts and polymorphs thereof |